CA19-9 in Potentially Resectable Pancreatic Cancer: Perspective to Adjust Surgical and Perioperative Therapy
作者： Werner Hartwig , Oliver Strobel , Ulf Hinz , Stefan Fritz , Thilo Hackert
DOI: 10.1245/S10434-012-2809-1
关键词:
摘要: Purpose In pancreatic cancer, genetic markers to aid clinical decision making are still lacking. The present study was designed determine the prognostic role of perioperative serum tumor marker carbohydrate antigen 19-9 (CA19-9) in adenocarcinoma, with a focus on implications for pre- and postoperative therapeutic consequences.
springer.com
sci-hub.se 参考文章(36)
Gilda da Cunha Santos, Neesha Dhani, Dongsheng Tu, Kayu Chin, Olga Ludkovski, Suzanne Kamel‐Reid, Jeremy Squire, Wendy Parulekar, Malcolm J Moore, Ming Sound Tsao, None, Molecular Predictors of Outcome in a Phase 3 Study of Gemcitabine and Erlotinib Therapy in Patients With Advanced Pancreatic Cancer: National Cancer Institute of Canada Clinical Trials Group Study PA.3 Cancer. ,vol. 116, pp. 5599- 5607 ,(2010) , 10.1002/CNCR.25393
Robles-Díaz G, Gómez E, Duarte-Rojo A, Mery Cm, Paz-Pineda F, [Does cholestasis change the clinical usefulness of CA 19-9 in pacreatobiliary cancer?]. Revista De Investigacion Clinica. ,vol. 53, pp. 511- 517 ,(2001)
Philip Q. Bao, Ramesh K. Ramanathan, Alyssa Krasinkas, Nathan Bahary, Barry C. Lembersky, David L. Bartlett, Steven J. Hughes, Kenneth K. Lee, A. James Moser, Herbert J. Zeh, Phase II study of gemcitabine and erlotinib as adjuvant therapy for patients with resected pancreatic cancer. Annals of Surgical Oncology. ,vol. 18, pp. 1122- 1129 ,(2011) , 10.1245/S10434-010-1401-9
Sherif R. Z. Abdel-Misih, Ioannis Hatzaras, Carl Schmidt, Tanios-Bekaii Saab, Dori Klemanski, Peter Muscarella, W. Scott Melvin, E. Christopher Ellison, Mark Bloomston, Failure of normalization of CA19-9 following resection for pancreatic cancer is tantamount to metastatic disease. Annals of Surgical Oncology. ,vol. 18, pp. 1116- 1121 ,(2011) , 10.1245/S10434-010-1397-1
Joshua G. Barton, John P. Bois, Michael G. Sarr, Christina M. Wood, Rui Qin, Kristine M. Thomsen, Michael L. Kendrick, Michael B. Farnell, Predictive and prognostic value of CA 19-9 in resected pancreatic adenocarcinoma. Journal of Gastrointestinal Surgery. ,vol. 13, pp. 2050- 2058 ,(2009) , 10.1007/S11605-009-0849-Z
Werner Hartwig, Thilo Hackert, Ulf Hinz, Matthias Hassenpflug, Oliver Strobel, Markus W. Büchler, Jens Werner, Multivisceral Resection for Pancreatic Malignancies: Risk-Analysis and Long-Term Outcome Annals of Surgery. ,vol. 250, pp. 81- 87 ,(2009) , 10.1097/SLA.0B013E3181AD657B
C. M. Halloran, P. Ghaneh, S. Connor, R. Sutton, J. P. Neoptolemos, M. G. T. Raraty, Carbohydrate antigen 19.9 accurately selects patients for laparoscopic assessment to determine resectability of pancreatic malignancy British Journal of Surgery. ,vol. 95, pp. 453- 459 ,(2008) , 10.1002/BJS.6043
Michele Reni, Stefano Cereda, Gianpaolo Balzano, Paolo Passoni, Alessia Rognone, Clara Fugazza, Elena Mazza, Alessandro Zerbi, Valerio Di Carlo, Eugenio Villa, Carbohydrate antigen 19-9 change during chemotherapy for advanced pancreatic adenocarcinoma Cancer. ,vol. 115, pp. 2630- 2639 ,(2009) , 10.1002/CNCR.24302
A KARACHRISTOS, N SCARMEAS, J HOFFMAN, CA 19-9 levels predict results of staging laparoscopy in pancreatic cancer Journal of Gastrointestinal Surgery. ,vol. 9, pp. 1286- 1292 ,(2005) , 10.1016/J.GASSUR.2005.06.008
Michele Reni, Gianpaolo Balzano, Giuseppe Aprile, Stefano Cereda, Paolo Passoni, Alessandro Zerbi, Maria Chiara Tronconi, Carlo Milandri, Piercarlo Saletti, Alessia Rognone, Clara Fugazza, Alessandro Magli, Nadia Di Muzio, Valerio Di Carlo, Eugenio Villa, Adjuvant PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) or gemcitabine followed by chemoradiation in pancreatic cancer: a randomized phase II trial. Annals of Surgical Oncology. ,vol. 19, pp. 2256- 2263 ,(2012) , 10.1245/S10434-011-2205-2